Breaking News

Aptamer Group Introduces Targeted Radiopharmaceutical Program

Aims to advance multiple assets towards in vivo validation and demonstrate the potential of the Optimer platform.

Author Image

By: Charlie Sternberg

Associate Editor

Aptamer Group plc, a developer of next generation synthetic binders for the life sciences industry, has launched a new targeted radiopharmaceutical program in collaboration with Radiopharmium Ltd, a UK-based specialist consultancy in radiopharmaceutical development. A key challenge in radiopharmaceuticals is maintaining the stability of the targeting molecule once it is carrying a radioactive payload. Aptamer’s data indicates that Optimer-based radioligands may offer improved stability compar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters